منابع مشابه
Novel target to kill CLL.
In this issue of Blood, Liu et al report on OSU-T315, a new agent that specifically disrupts the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) pathway and shows high proapoptotic activity against chronic lymphocytic leukemia (CLL) cells, which may indicate a potential therapeutic application in this disease
متن کاملPharmacogenetics: using DNA to optimize drug therapy.
Pharmacogenetics is a growing field of research that focuses on the interaction between genetics and drug therapy. Relationships between genetic variation and drug effect have been observed for a growing number of commonly used drugs. Validation studies may soon define the use of these relationships in clinical practice, moving the field toward routine application. Currently, there are only a f...
متن کاملNew agents in the treatment of CLL.
Chemoimmunotherapy has resulted in high complete remission rates and long remission duration in patients with chronic lymphocytic leukemia (CLL) but relapses occur and curative strategies still need to be developed. A wealth of new agents with a wide variety of mechanisms of action against CLL are currently in clinical trials. Twelve of these agents, which are in various stages of development v...
متن کاملPropose of a novel method to simulate and optimize a polymer optical fiber daylighting system
Optical fiber day lighting systems help the efficiency of using solar energy in the lighting system in domestic, industrial and agricultural sectors. A lot of work has been done on these systems, but the lack of a reliable simulation method to reduce the tolerance, time and cost is evident. In this regard, in this paper, a novel method based on two powerful Optifiber and Zemax software has bee...
متن کاملNovel agents for anti-platelet therapy
Anti-platelet therapy plays an important role in the treatment of patients with thrombotic diseases. The most commonly used anti-platelet drugs, namely, aspirin, ticlopidine, and clopidogrel, are effective in the prevention and treatment of cardio-cerebrovascular diseases. Glycoprotein IIb/IIIa antagonists (e.g., abciximab, eptifibatide and tirofiban) have demonstrated good clinical benefits an...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Oncology Times
سال: 2018
ISSN: 0276-2234
DOI: 10.1097/01.cot.0000535068.12266.62